

ANTITHROMBOTIC MANAGEMENT OF PATIENTS WITH ATRIAL FIBRILLATION

Aims & Scope

Ischemic stroke is one of the serious and feared complications of atrial fibrillation, the world's most common sustained arrhythmia. Appropriate antithrombotic therapy is therefore the cornerstone of the treatment of patients with atrial fibrillation. Recently, results of land mark trials on new antithrombotic drugs and devices to prevent stroke became available as well as new insights in stroke and bleeding risk assessment. All of these developments have a profound impact on current and future clinical practice. This special issue aims to provide a comprehensive, evidence based overview of all the aspects associated with adequate antithrombotic management of atrial fibrillation patients and portrait (desired) future developments.

Proposed articles and contributing authors

1. Intro (R Pisters, MD, Maastricht, the Netherlands)
2. Stroke risk assessment
(GYH Lip, MD PhD, City Hospital Birmingham, UK) CONFIRMED
3. Value of echocardiography in stroke risk assessment
(T Dinh, MD, Heerlen, the Netherlands)
4. Bleeding risk assessment
(R Pisters, MD, Maastricht, the Netherlands)
5. (Old &) New antithrombotic drugs
(H ten Cate, MD PhD Maastricht, the Netherlands)
6. Strategies to optimize time in therapeutic range
(R Nieuwlaat, PhD, Population Health Research Institute Hamilton, Canada)
7. Peri-procedural antithrombotic bridging
(PW Kamphuisen, MD PhD, Academic Hospital Amsterdam, the Netherlands)
8. Ablation related antithrombotic management
(P Kirchhof, MD PhD, University Hospital Munster, Germany)
9. Antithrombotic management in the acute coronary syndrome setting
(A Rubboli, MD PhD, Maggiore Hospital, Bologna, Italy) CONFIRMED
10. Conclusions (R Pisters, MD, Maastricht, the Netherlands)